'Asco annual meeting' diaporamas de présentation

Genes and Function: The Rewriting of our <br />Textbooks of Pathology

Genes and Function: The Rewriting of our <br />Textbooks of Pathology. Presented By David Hafler at 2014 ASCO Annual Meeting. Slide 2. Presented By David Hafler at 2014 ASCO Annual Meeting. Slide 3. Presented By David Hafler at 2014 ASCO Annual Meeting. Slide 4.

526 views • 43 slides

Presented By Alan Venook at 2014 ASCO Annual Meeting

<br />CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma of the colon or rectum <br />. Presented By Alan Venook at 2014 ASCO Annual Meeting. Slide 2.

904 views • 36 slides

Presented By Franco Cavalli at 2014 ASCO Annual Meeting

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients ineligible for bone marrow transplantation . Presented By Franco Cavalli at 2014 ASCO Annual Meeting.

618 views • 31 slides

Highlights of the Day: <br />LYMPHOMA

Highlights of the Day: <br />LYMPHOMA. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Abstracts. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?. Presented By Sonali Smith at 2014 ASCO Annual Meeting. Slide 4.

441 views • 28 slides

Slide 1

Slide 1. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Conflict of Interest Disclosure. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Limited Advancement in 2nd-Line Therapy. Presented By Maurice Perol at 2014 ASCO Annual Meeting. Ramucirumab and Angiogenesis.

417 views • 26 slides

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Disclosure. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Slide 3.

546 views • 25 slides

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. Presented By Christopher Sweeney at 2014 ASCO Annual Meeting. A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer.

552 views • 24 slides

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting. PD-1/ PD-L1 pathway in suppressing anti-tumor immunity .

725 views • 24 slides

Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function Suppression<br /> vs Tamoxifen plus Ovarian Function Suppression<br />in Premenopausal Women <br />with Hormone Receptor Positive Early Breast Cancer: <br />Joint Analysis of IBCSG TEXT and SOFT.

477 views • 22 slides

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting.

400 views • 21 slides

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Efficacy and Safety of the Anti-PD-1 <br />Monoclonal Antibody Pembrolizumab (MK-3475) in 411 Patients With Melanoma. Presented By Antoni Ribas at 2014 ASCO Annual Meeting. Disclosures. Presented By Antoni Ribas at 2014 ASCO Annual Meeting.

877 views • 20 slides

Highlights of the Day III<br />Genitourinary (Nonprostate) Cancer

Highlights of the Day III<br />Genitourinary (Nonprostate) Cancer. Presented By Toni Choueiri at 2014 ASCO Annual Meeting. Disclosures. Presented By Toni Choueiri at 2014 ASCO Annual Meeting. Learning Objectives. Presented By Toni Choueiri at 2014 ASCO Annual Meeting. Slide 4.

354 views • 19 slides

Presented By John Byrd at 2014 ASCO Annual Meeting

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial. Presented By John Byrd at 2014 ASCO Annual Meeting. Background.

349 views • 18 slides

Presented By Mario Sznol at 2014 ASCO Annual Meeting

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL) . Presented By Mario Sznol at 2014 ASCO Annual Meeting. Disclosures.

337 views • 18 slides

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial. Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting. Disclosure.

357 views • 18 slides

Presented By Joyce Liu at 2014 ASCO Annual Meeting

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone in Recurrent Platinum-sensitive Ovarian Cancer. Presented By Joyce Liu at 2014 ASCO Annual Meeting.

310 views • 17 slides

Presented By Wolfgang Wick at 2014 ASCO Annual Meeting

363 views • 17 slides

Slide 1

Slide 1. Presented By Hongchao Pan at 2014 ASCO Annual Meeting. Slide 2. Presented By Hongchao Pan at 2014 ASCO Annual Meeting. Slide 3. Presented By Hongchao Pan at 2014 ASCO Annual Meeting. Slide 4. Presented By Hongchao Pan at 2014 ASCO Annual Meeting. Slide 5.

287 views • 17 slides

Highlights: Myeloma Oral Session

Highlights: Myeloma Oral Session. Presented By Saad Usmani at 2014 ASCO Annual Meeting. Learning Objectives. Presented By Saad Usmani at 2014 ASCO Annual Meeting. The Context. Presented By Saad Usmani at 2014 ASCO Annual Meeting. The Challenges.

290 views • 14 slides

Presented By Xabier Garcia-Albeniz at 2014 ASCO Annual Meeting

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Presented By Xabier Garcia-Albeniz at 2014 ASCO Annual Meeting. Background. Presented By Xabier Garcia-Albeniz at 2014 ASCO Annual Meeting.

312 views • 14 slides